PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
Retrieved on:
Wednesday, November 9, 2022
Biotechnology, Pharmaceutical, General Health, Health, FDA, Health Technology, Clinical Trials, Other Health, Online, COPD, Safety, Research, Risk, Death, Link, Efficacy, Journal of Asthma and Allergy, Company, ADULT, Salbutamol, Conference, Papis Loveday, Inhaler, Risk factor, AstraZeneca, Dermatology, Spirometry, Internet, Jean-Jacques Bourdin, MDI, ICS, Science, Diagnosis, Global Initiative for Asthma, Patient, B93, Observational study, Ageing, ERS, BDA, SCS, Chronic lung disease, Week, Biopharmaceutical, Clare Lloyd, CDC, Veni, vidi, vici, Gastroenterology, Hospital, Atmosphere, Medicine, Clinical trial, Growth, NDA, Immunology, AES, ClinicalTrials.gov, Child, Rheumatology, Nature Research, Mortality, Protein Data Bank (file format), Budesonide, ID, Disease, Thomas Ford Chipp, Metabolism, Pharmaceutical industry, Silviculture, Asthma, FEV1, Oncology, Common
PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.
Key Points:
- PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.
- In March 2018, AstraZeneca and Avillion signed an agreement to advance PT027 through a global clinical development program for the treatment of asthma.
- Following the successful approval of PT027, AstraZeneca has the option, upon certain financial payments, to commercialize the medicine in the US.
- The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.